Free Design Audit Available - Click Here for Details

Carthera wins U.S., EU orphan drug designation for SonoCloud

Carthera announced today that it received FDA and European orphan drug designation (ODD) for the use of carboplatin with its SonoCloud.

The designation allows Paris, France-based Carthera to use carboplatin chemotherapy in the treatment of malignant glioma. Carthera conducts this treatment through the use of SonoCloud, a device that emits ultrasound to temporarily increase the permeability of blood vessels in the brain, improving therapeutic molecule delivery.

Sign up for Blog Updates